Royce & Associates LP Purchases 75,702 Shares of Pediatrix Medical Group, Inc. $MD

Royce & Associates LP raised its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 42.3% in the fourth quarter, HoldingsChannel reports. The firm owned 254,748 shares of the company’s stock after buying an additional 75,702 shares during the quarter. Royce & Associates LP’s holdings in Pediatrix Medical Group were worth $5,449,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Victory Capital Management Inc. lifted its position in shares of Pediatrix Medical Group by 30.7% during the 3rd quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock valued at $69,114,000 after buying an additional 968,553 shares in the last quarter. American Century Companies Inc. boosted its stake in Pediatrix Medical Group by 38.9% in the 3rd quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock worth $44,940,000 after purchasing an additional 751,109 shares during the period. Allspring Global Investments Holdings LLC bought a new position in Pediatrix Medical Group in the 4th quarter worth approximately $13,613,000. Ameriprise Financial Inc. boosted its stake in Pediatrix Medical Group by 175.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock worth $10,683,000 after purchasing an additional 474,186 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in Pediatrix Medical Group by 669.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company’s stock worth $6,832,000 after purchasing an additional 414,216 shares during the period. 97.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on MD. Deutsche Bank Aktiengesellschaft set a $19.00 price target on Pediatrix Medical Group in a research note on Friday, February 20th. UBS Group upped their price target on Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Friday, March 27th. Jefferies Financial Group restated a “buy” rating and issued a $27.00 price target on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Finally, Truist Financial upped their price target on Pediatrix Medical Group from $21.00 to $23.00 and gave the stock a “hold” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $22.50.

Insider Activity

In other news, Director Shirley A. Weis sold 36,028 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total transaction of $855,665.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.80% of the stock is owned by company insiders.

Pediatrix Medical Group Stock Down 0.3%

Shares of MD opened at $21.54 on Friday. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of 10.46 and a beta of 0.70. Pediatrix Medical Group, Inc. has a 1 year low of $11.84 and a 1 year high of $24.99. The business’s 50 day simple moving average is $21.98 and its 200-day simple moving average is $21.73. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.33 and a quick ratio of 1.33.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. The business had revenue of $476.20 million for the quarter, compared to analysts’ expectations of $465.83 million. Pediatrix Medical Group had a return on equity of 19.94% and a net margin of 9.02%.The company’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.33 EPS. As a group, equities analysts expect that Pediatrix Medical Group, Inc. will post 2.08 earnings per share for the current fiscal year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.